Skip to main content
Article thumbnail
Location of Repository

Changes in cognitive domains during three years in patients with Alzheimer's disease treated with donepezil

By Cecilia M Persson, Åsa K Wallin, Sten Levander and Lennart Minthon
Topics: Research Article
Publisher: BioMed Central
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. (1996). A psychometric evaluation of dementia rating scales. European Psychiatry
  2. (1992). Alzheimer Disease Assessment Scale: a subtest analysis. Alzheimer Dis Assoc Disord
  3. (1997). Alzheimer's Disease Assessment Scale: Reliability and Validity in a Multicenter Clinical Trial. International Psychogeriatrics
  4. (1996). AM: Mini-Mental State Examination (MMSE) and the Modified MMSE (3MS): A psychometric comparison and normative data. Psychological Assessment
  5. (1994). American Psychiatric Association: DSM-IV: Diagnostic and statistical manual of mental disorders 4th edition.
  6. (2006). C: A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease.
  7. (2005). Cognitive performance in Alzheimer's disease patients receiving rivastigmine for up to 5 years.
  8. (1997). Community Screening for Dementia: The Mini Mental State Exam (MMSE) and Modified Mini-Mental State Exam (3MS) Compared.
  9. (2005). E: Psychometric Properties of the Folstein Mini-Mental State Examination. Assessment
  10. (1984). EM: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology
  11. (2006). Eser E: The validity and reliability of the Turkish version of Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) in patients with mild and moderate Alzheimer's disease and normal subjects.
  12. (1994). Factor structure and reliability of the Alzheimer's Disease Assessment Scale in a multicenter trial with linopirdine.
  13. (2004). FiveYear Outcome of Cholinergic Treatment of Alzheimer's Disease: Early Response Predicts Prolonged Time until Nursing Home Placement, but Does Not Alter Life Expectancy. Dementia and Geriatric Cognitive Disorders
  14. (1996). Gracon SI: Cardinal features of cognitive dysfunction in Alzheimer's disease: a factor-analytic study of the Alzheimer's Disease Assessment Scale.
  15. Hofman A: Incidence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts.
  16. (2000). Ieni JR: Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open-label study. European Neuropsychopharmacology
  17. (2004). J-M: The usefulness of the Korean version of modified Mini-Mental State Examination (KmMMSE) for dementia screening in community dwelling elderly people. BMC Public Health
  18. (1984). KL: A new rating scale for Alzheimer's disease. The american journal of psychiatry
  19. (2007). L: An estimate of the total worldwide societal costs of dementia in 2005. Alzheimer's and Dementia
  20. (2007). Long-term cognitive benefits of donepezil in Alzheimer's disease: A retrospective comparison between 1994–1999 and 2000–2004. Geriatrics and Gerontology International
  21. (2000). Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet
  22. (1975). Mini-mental state" – A practical method for grading the cognitive state of patients for the clinician.
  23. (2006). Ohno T: Cognitive dysfunction induced by sequential injection of amyloid-β and ibotenate into the bilateral hippocampus; protection by memantine and MK-801.
  24. (2005). Prevalence of dementia in the elderly in Europe. European Neuropsychopharmacology
  25. (2006). R: 3-Year Study of Donepezil Therapy in Alzheimer's Disease: Effects of Early and Continuous Therapy. Dement Geriatr Cogn Disord
  26. (2005). REAL.FRgroup t: Rapid cognitive decline: Searching for a definition and predictive factors among elderly with Alzheimer's disease.
  27. (2006). RJ: Donepezil for dementia due to Alzheimer's disease. Cochrane Database Syst Rev
  28. (2004). Size of the treatment effect on cognition of cholinesterase inhibition in Alzheimer's disease.
  29. (1977). Statistical Analyses for the Behavioral Sciences New Jersey: Lawrence Erlbaum Ass.;
  30. (2001). Subbiah P: A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology
  31. (2007). The clinical meaningfulness of ADAS-Cog changes in Alzheimer's disease patients treated with donepezil in an open-label trial.
  32. Trabucchi M: A qualitative analysis of the Mini Mental State Examination on Alzheimer's disease patients treated with cholinesterase inhibitors.
  33. (2008). Treatment of a Whole Population Sample of Alzheimer's Disease with Donepezil over a 4-Year Period: Lessons Learned. Dement Geriatr Cogn Disord
  34. (1990). Yesavage JA: Factor Analysis and Preliminary Validation of the Mini-Mental State Examination from a Longitudinal Perspective. International Psychogeriatrics

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.